Page 5 - HIV/AIDS Guidelines

• New recommendation to not use HIV PIs and non-nucleoside reverse transcriptase inhibitors (NNRTIs)
with rifapentine
• Addition of information on interactions of boceprevir and telaprevir with different ARV drugs and related
recommendations
• Update of interactions between different ritonavir-boosted PI and HMG-CoA reductase inhibitors.

Prevention of Secondary HIV Transmission

This section is updated to discuss the role of effective ART in preventing HIV transmission. The updated
section also indicates evidence-based interventions available to assist providers with HIV risk behavior
identification and counseling.

Additional Updates
Minor revisions have also been made to the following sections:

• Treatment Goals
• What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient (new information
regarding adverse effects of raltegravir)
• HIV and Illicit Drug Users (new drug interaction added to Table 11 included in the section)
• Adherence to Antiretroviral Therapy
• Adverse Effects of Antiretroviral Agents (and accompanying Table 13)

• Drug Characteristics Tables (Appendix B)

a
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = data from randomized controlled trials; II = data from well-designed nonrandomized trials or observational
cohort studies with long-term clinical outcomes; III = expert opinion

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents iii

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.